Cytex President and Co-founder Bradley Estes, PhD, presents at Orthopedic Research Society Conference in Austin, TX. February 2-5, 2019.

Bradley Estes, PhD, Cytex President and COO, presented the latest results from studies the company has been conducting in cooperation with researchers at North Carolina State University School of Veterinary Medicine.  In these studies, Cytex and NC State investigators demonstrated the ability of Cytex patented implants to repair cartilage damage in a model of osteoarthritis. […]

Continue reading


Cytex Shareholders Approve Organizational Changes, Elect New Directors.

Cytex shareholders voted unanimously to approve the following changes to company management: Farshid Guilak, PhD, was elected Executive Chairman of the Board; Bradley Estes, PhD, was promoted to President and Chief Operating Officer and was elected to the Cytex Board of Directors, and; David Pritchard, Cytex CEO, was elected to the Cytex Board of Directors.  […]

Continue reading


Cytex Brings in New Chief Executive Officer.

Cytex is pleased to announce that David Pritchard has joined the company, effective immediately, as Chief Executive Officer.  Mr. Pritchard is an experienced biotechnology executive who has previously served as CEO of several startups and early stage companies.  He has worked in the biotech industry in Boston, San Diego, San Francisco, Philadelphia, the Pacific Northwest […]

Continue reading


Dr. Vince Willard, Director of Regenerative Therapies, Co-Authors Two Papers on Genetic Engineering

Dr. Vince Willard recently co-authored two papers studying applications of gene editing of stem cells to prevent inflammation. One paper, entitled “CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues,” published in the May 2017 edition of Arthritis & Rheumatology. The other paper, “Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop […]

Continue reading